Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2019 Feb 5. pii: S1542-3565(19)30091-6. doi: 10.1016/j.cgh.2019.01.044. [Epub ahead of print]

Long-Term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection.

Author information

1
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
2
Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea.
3
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea.
4
Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
5
Department of Internal Medicine, Keimyung University College of Medicine, Daegu, South Korea.
6
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
7
Department of Internal Medicine, Sungkyunkwan University College of Medicine, Kangbuk Samsung Hospital, Seoul, South Korea.
8
Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea.
9
Department of Internal Medicine, Pusan National University College of Medicine, Busan, South Korea.
10
Department of Internal Medicine, Ajou University School of Medicine, Suwon, South Korea.
11
Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea.
12
Department of Internal Medicine, Hanyang University Guri Hospital, Guri, South Korea.
13
Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea.
14
Department of Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, South Korea.
15
Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea.
16
Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, South Korea.
17
Department of Medical Information and Administration, College of Health Science, Jungwon University, Goesan, South Korea.
18
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: gihankhys@yuhs.ac.

Abstract

Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few "prospective" studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

PMID:
30731195
DOI:
10.1016/j.cgh.2019.01.044

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center